603669 Lionco Pharmaceutical Group
- 8.51
- -0.06-0.70%
Lionco Pharmaceutical Group News
Lionco Pharmaceutical Group (603669.SH): Subsidiary participates in the national pharmaceutical centralized procurement and plans to be selected.
On December 13, Gelonghui reported that Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary Hainan Lionco Pharmaceutical Co., Ltd. participated in the tenth batch of national centralized procurement organized by the National Organization for Pharmaceutical Joint Procurement Office (referred to as the 'Joint Procurement Office'). According to the public announcement of the proposed selection results of national centralized procurement released by the Joint Procurement Office, Lionco Pharmaceutical's product, injectable ceftazidime sodium, is proposed to be selected for this centralized procurement. The sales revenue of injectable ceftazidime sodium from Lionco Pharmaceutical's wholly-owned subsidiary in 2023 amounted to 0 million yuan, accounting for 0% of the company's revenue for the year 2023; sales for the first three quarters of 2024.
Revenues Not Telling The Story For Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) After Shares Rise 29%
Is Lionco Pharmaceutical GroupLtd (SHSE:603669) Using Debt Sensibly?
Company Report for the Third Quarter of 2024 (after correction)
Announcement on additional information to the 2024 Third Quarter Report
lionco pharmaceutical group (603669.SH) subsidiary cephalosporin sodium for injection passed the generic drug consistency evaluation.
Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary Hainan Lionco Pharmaceutical Co., Ltd. (referred to as "...
Lingkang Pharmaceutical: Third Quarter Report 2024
Third Quarter Report 2024
Lionco Pharmaceutical Group (603669.SH) released its performance for the first three quarters, with a net loss of 46.89 million yuan.
lionco pharmaceutical group (603669.SH) disclosed the third quarter report of 2024, achieving revenue in the first three quarters of the company...
lionco pharmaceutical group (603669.SH): a net loss of 46.8899 million yuan in the first three quarters.
Gelonghui October 30th | Lionco Pharmaceutical Group (603669.SH) released its third-quarter report, with revenue of 0.231 billion yuan in the first three quarters, a year-on-year increase of 53.34%, a net loss of 46.8899 million yuan, a non-GAAP net loss of 90.86 million yuan, and basic earnings per share of -0.07 yuan.
Lionco Pharmaceutical GroupLtd (SHSE:603669) Shareholders Are up 16% This Past Week, but Still in the Red Over the Last Three Years
Lionco Pharmaceutical Gets Nod to Amend Cefuroxime Sodium for Injection's Production Standards
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
Lionco Pharmaceutical Group (603669.SH): net loss of 40.4002 million yuan in the first half of the year.
On August 23, Gelonhui reported the semi-annual report for the year 2024, with revenue of 0.141 billion yuan, a year-on-year increase of 25.29%; net income attributable to shareholders of the listed company was -40.4002 million yuan.
Lionco Pharmaceutical Group (603669.SH): Subsidiary Cefoperazone Sodium for Injection passes the generic drug consistency evaluation.
On August 14, Gelonhui reported that Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary, Hainan Lionco Pharmaceutical Co., Ltd. (referred to as Lionco Pharmaceutical), recently received the approval notice of the supplementary drug application for the injection of cefoperazone sodium (referred to as the pharmaceutical) issued by the State Administration of Drug Administration. The pharmaceutical has passed the consistency evaluation of generic drug quality and efficacy. Cefoperazone sodium for injection is mainly used for: lower respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections, and meningitis caused by pneumococcus or influenza bacillus.
Lionco Pharmaceutical's Unit to Trial Esomeprazole Magnesium Sodium Bicarbonate Dry Suspension
Lionco Pharmaceutical Group (603669.SH): Its subsidiary has obtained a notice of approval for clinical trials of drugs.
On July 17, Grail Street reported that Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary Hainan Lionco Pharmaceutical Co., Ltd. (referred to as "Lionco Pharmaceutical") recently obtained the Drug Clinical Trial Approval Notice for esomeprazole magnesium and sodium bicarbonate dry mixed suspension (I) issued by the Drug Evaluation Center (CDE) of the National Drug Administration. Esomeprazole magnesium and sodium bicarbonate dry mixed suspension (I) is clinically intended for the prevention of the recurrence of gastroesophageal reflux disease (GERD) symptoms in patients with cured esophagitis - long-term treatment and GERD symptom control; which requires continuous treatment.
Lionco Pharmaceutical Group (603669.SH): Clinical trial of esomeprazole magnesium and sodium bicarbonate dry mixed suspension (Ⅰ) approved.
Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary, Hainan Lionco Pharmaceutical Co., Ltd., recently obtained...
Lionco Pharma Ties Up With Laboratoire Bailly-Creat on International Sales
No Data